Abstract
Noninvasive axillary lymph node staging was investigated using [131I]murine monoclonal antibody B72.3 in 16 patients with breast cancer scheduled for axillary dissection. [131I]B72.3 was injected into ipsilateral finger webs or around the breast biopsy. Scintigraphy to 72 h and gamma-counting/immunohistochemistry of nodes were performed. Specific antibody uptake (%ID/g) and the ratio of specific:nonspecific antibody uptake were not significantly different in tumor-positive versus tumor-negative nodes, suggesting that [131I]B72.3 is unsuitable to discriminate axillary node tumor involvement.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antibodies, Monoclonal
-
Antibodies, Neoplasm
-
Antigens, Neoplasm / analysis
-
Breast Neoplasms / diagnostic imaging*
-
Breast Neoplasms / pathology
-
Female
-
Glycoproteins / analysis
-
Humans
-
Immunohistochemistry
-
Iodine Radioisotopes* / pharmacokinetics
-
Lymph Nodes / diagnostic imaging
-
Lymphatic Metastasis / diagnostic imaging*
-
Lymphatic Metastasis / pathology
-
Neoplasm Staging
-
Radioimmunodetection*
-
Radiopharmaceuticals* / pharmacokinetics
Substances
-
Antibodies, Monoclonal
-
Antibodies, Neoplasm
-
Antigens, Neoplasm
-
B72.3 antibody
-
Glycoproteins
-
Iodine Radioisotopes
-
Radiopharmaceuticals
-
tumor-associated antigen 72